Research for Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - aVenture News
Avenzo Therapeutics | Developing the next generation of oncology therapies for patients.
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
SAN DIEGO, Calif. – June 1, 2026 – Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today reported updated clinical data from the Phase 1 portion of its ongoing Phase 1/2 clinical study of AVZO-021, its potentially differentiated cyclin-dependent kinase 2 (CDK2) selective inhibitor. The updated data demonstrated clinical activity in heavily pretreated patients with hormone receptor-positive (HR+)/human epidermal growth fa